Lipocine Price to Free Cash Flow Ratio 2012-2025 | LPCN

Lipocine price to free cash flow ratio from 2012 to 2025. Price to free cash flow ratio can be defined as

Lipocine Price to Free Cash Flow Ratio 2012-2025 | LPCN

Lipocine price to free cash flow ratio from 2012 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.7B
Zoetis (ZTS)$67.1B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$45.5B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$20.4B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$15B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.9B
Corcept Therapeutics (CORT)$7.3B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.6B
Madrigal Pharmaceuticals (MDGL)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B